

Thursday 5 September

- 12.50 **Welcome Address**  
 Maria Antonietta D'Agostino and Nigil Haroon  
*Congress Presidents*
- The Translational Grand Debate: Decoding the Gut-Joint Connections in SpA**
- 13.00 **INV1 Motion: Microbiome as key pathophysiology mechanism in SpA**  
 Tejpal Gill, USA
- 13.20 **INV2 Counter: Gut tissue as key pathophysiology mechanism in SpA**  
 Francesco Ciccia, Italy
- SESSION 1 Clinical Concepts: Can we revise the concept of prognosis?**
- 13.40 **INV3 What is a severe axSpA?**  
 Felicie Costantino, France
- 14.00 **INV4 Metabolic signature in PsA and SpA**  
 Margarida Souto-Carneiro, Germany
- 14.20 **INV5 Refractory SpA: Current understanding**  
 Filip Van den Bosch, Belgium
- Selected Oral Presentations I*
- 14.40 **O1 Enhanced type 1 interferon signature in axial spondyloarthritis patients unresponsive to secukinumab treatment**  
 Adisson Pacheco, Toronto, Canada
- 14.52 **O2 Anxiety disorders in spondyloarthritis patients on biologic therapy registered in Reuma.pt: Prevalence, role of disease-related factors and influence of biologic therapy**  
 Duarte Augusto, Lisboa, Portugal
- 15.04 **O3 Complement activation and spinal radiographic progression in patients with radiographic axial spondyloarthritis treated with TNF-inhibition over 2 years: Observations from a randomized controlled trial (CONSUL)**  
 Clara Mistegaard, Aarhus, Denmark

Thursday 5 September

- 15.16 Coffee Break & Poster Session A
- SESSION 2 Lessons learned from the EMM world**
- 16.15 **INV6 Remission-induction in IBD: Where are we now**  
 Séverine Vermeire, Belgium
- 16.35 **INV7 Getting rid of the tissue-resident memory T cells in psoriasis**  
 Speaker to be confirmed
- Selected Oral Presentations II*
- 16.55 **O4 Early-life colonisation by intestinal bacteria programs the immune system to permit development of SpA**  
 India Brough, Oxford, UK
- 17.07 **O5 RORγt+ γδ T cells are critical players in spondyloarthritis**  
 Koen Venken, Ghent, Belgium
- 17.19 **O6 Tissue resident memory Th17 (TRM17) cells are the predominant source of interleukin (IL)-17 in spondyloarthritis, produce IL-17 independent of IL-23 and are epigenetically regulated by bromodomain containing 1 (BRD1)**  
 Liye Chen, Oxford, UK
- The Ghent SpA Oration**
- 17.31 **INV8 50 years of HLA-B27**  
 Paul Bowness, UK
- 18.00 **Welcome Reception and Walking Dinner**

Friday 6 September

**SESSION 3 Cells to cytokines: Learning from others**

- 08.30 **INV9** **Inside the box: Biology of IL23 the ups and downs for SpA**  
Iannis Adamopoulos, USA
- 08.50 **INV10** **Outside the box: Learning about neutrophils**  
Ricardo Grieshaber-Bouyer, Germany
- Selected Oral Presentations III**
- 09.10 **07** **Ly6G+CXCR2-CD101- granulocytes regulate inflammation in axial spondyloarthritis**  
Christian Schütz, Herne, Germany
- 09.22 **08** **Proteomic, transcriptomic, and T-cell receptor (TCR) profiling of synovial integrin-expressing (InEx) T cells in axial spondyloarthritis (axSpA)**  
Zoya Qaiyum, Toronto, Canada

**SESSION 4 Cells to cytokines: What is new in SpA**

- 09.34 **INV11** **MIF-Neutrophil axis in SpA**  
Akihiro Nakamura, Canada
- 09.54 **INV12** **gd T cells in SpA**  
Robin Dart, UK
- 10.15 Coffee Break & Poster Session B
- The Clinical Grand Debate**  
**Discrepancy in response to current therapy:**  
**Are we choosing the right target?**
- 11.15 **INV13** **Motion: Control of pain is the key outcome in SpA**  
Kurt de Vlam, Belgium
- 11.35 **INV14** **Counter motion: Control of inflammation is the key outcome in SpA**  
Atul Deodhar, USA

Friday 6 September

**Selected Oral Presentations IV**

- 12.00 **09** **Identifying novel molecular signatures in psoriatic arthritis through high-throughput proteomic analysis of immune cells**  
Jesús Eduardo Martín-Salazar, Córdoba, Spain
- 12.12 **010** **Associations and impact of kinesiophobia on patient reported outcomes and performance-based mobility measures in patients with axial spondyloarthritis**  
David Kiefer, Herne, Germany
- 12.24 **011** **The Assessment of SpondyloArthritis International Society (ASAS) definition of difficult-to-manage axial spondyloarthritis**  
Denis Poddubnyy, Berlin, Germany
- 12.36 Lunch
- Keynote Lecture - Cutting edge basic science: Unveiling discoveries for SpA**
- 13.40 **INV15** **From structure to drug discovery**  
Savvas Savvides, Belgium
- Selected Oral Presentations V**
- 14.10 **012** **Extl3 involved in the regulation of endochondral ossification in axial SpA**  
Stéphane Hilliquin, Paris, France
- 14.22 **013** **Spondyloarthritis patient cells display TNF hyperresponsiveness through enhanced p65 nuclear translocation**  
Fatemeh Navid, Bethesda, USA
- 14.34 **014** **PD-1+TIGIT+LAG3+ CD8+ T cells with features of exhausted phenotype characterize chronic joint inflammation in axial spondyloarthritis**  
Michael Tang, Toronto, Canada
- 14.46 **015** **Impairment of regulatory T cells stability in axial spondyloarthritis: Role of EZH2 and pSTAT5**  
Natacha Bessis, Bobigny, France

## Friday 6 September

### SESSION 5 Lessons learned from deep tissue analysis

- 15.00 **INV16** **Tissue based analysis in psoriatic arthritis**  
Stefano Alivernini, Italy
- 15.20 **INV17** **Resolving disease heterogeneity through molecular pathology: towards precision rheumatology**  
Costantino Pitzalis, UK

15.40 Coffee Break & Poster Session C

### SESSION 6 Clinical conundrums in SpA

- 16.40 **INV18** **Where are the USpA patients?**  
Maxime Breban, France
- 17.00 **INV19** **Clinical evaluation in SpA: Contemplating its role in the future**  
Lianne Gensler, USA
- 17.20 **INV20** **Soluble biomarkers in SpA: still pretentious?**  
Dirk Elewaut, Belgium

## Saturday 7 September

### SESSION 7 Revolutionizing healthcare: The transformative power of AI

- 08.30 **INV21** **AI in axSpA imaging**  
Keno Bressemer, Germany
- 08.50 **INV22** **Reducing imprecision in precision medicine**  
Igor Jurisica, Canada

### SESSION 8 Flash Oral Presentations

- 09.10 **O16** **Global distribution and determinants of diagnostic delay across diverse spondyloarthritis entities: Data from the international ASAS-Perspa Study**  
Nelly Ziade, Beirut, Lebanon
- 09.20 **O17** **Minimally invasive ultrasound-guided biopsy of the common extensor tendon enthesis: A cadaveric study to standardize the technique**  
Chiara Rizzo, Palermo, Italy
- 09.30 **O18** **Macrophage migration inhibitory factor and hypoxia-inducible factor 1-alpha may play a role in maintaining intestinal homeostasis through regulation of occludin and claudin-1 expression**  
Shaghayegh Foroozan Boroojeni, Toronto, Canada
- 09.40 **O19** **Integrative host-microbiome profiling in treatment-naïve spondyloarthritis shows oxidative stress-induced dysbiosis and links the B2 enterotype to disease activity and treatment response**  
Emilie Dumas, Ghent, Belgium
- 09.50 **O20** **Low disease activity in real-life patients with a diagnosis of axial spondyloarthritis: An achievable target?**  
Augusta Ortolan, Rome, Italy
- 10.00 **O21** **Effectiveness and cost-effectiveness of patient-initiated follow-up supported by asynchronous telemonitoring in spondylo-arthritis (TeleSpA-study): A pragmatic multicentre randomised controlled trial**  
Kasper Hermans, Maastricht, The Netherlands
- 10.10 Coffee Break & Poster Session D

**SESSION 9      The tapestry of pain: Mechanisms to management**

- 11.10    **INV23**    **Biology of pain in arthritis**  
Anne-Marie Malfait, Chicago, USA
- 11.30    **INV24**    **fMRI of pain**  
Andreas Hess, Erlangen-Nürnberg, Germany
- 11.50    **INV25**    **Current concepts in managing widespread pain**  
Neil Basu, Glasgow, UK

**SESSION 10     Forward Bound: Navigating the future landscape of SpA**

Selected Oral Presentations VI

- 12.10    **O22**      **TRABID: A novel therapeutic target for axial spondyloarthritis**  
Archita Srinath, Toronto, Canada
- 12.22    **O23**      **Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis**  
Chanhyeok Jeon, Seoul, Republic of Korea
- 12.34    **O24**      **Disease activity outcomes with the IL-17A- and IL-17F-inhibiting nanobody sonelokimab in patients with active psoriatic arthritis (PsA): Week 12 results from the Phase 2 ARGO trial**  
Georg Schett, Erlangen, Germany
- 12.36    **INV26**    **The future of SpA therapeutics, challenges and promises**  
Georg Schett, Erlangen, Germany
- 12.56            **Closing Remarks**  
Maria Antonietta D'Agostino and Nigil Haroon  
*Congress Presidents*  
Dirk Elewaut and Filip Van den Bosch  
*Local Organisers*
- 13.10            **Farewell Reception**